Roche also achieved operational growth. Core operating profit grew by 13 per cent and net profit according to IFRS by as much as 58 per cent. In addition to the pharma division, diagnostics also developed positively. New molecular tests and sequencing technologies provided impetus despite price pressure in China. Ten active ingredients in the pipeline are advancing into the decisive phase III. Positive study data were obtained for breast cancer and multiple sclerosis, among others. Roche is forecasting further growth in the mid-single-digit range for 2026 and is planning its 39th consecutive dividend increase. The Group combines solid financials with a broad-based innovation agenda.
Press release of "F. Hoffmann-La Roche Ltd" dated 29 January 2026